Should We Abandon Ezetimibe?

August 2008
Current Medical Literature: Cardiology;2008, Vol. 27 Issue 3, p77
Academic Journal
The article discusses a study on the clinical benefits of ezetimibe in decreasing lower density lipoprotein cholesterol alone or combined with statin. A randomized trial was used to evaluate the effects of ezetimibe. The results of the study show that its use may be effective and safe but finds no supporting evidence that it improves clinical outcome. It recommends the use of statin as the first line treatment in its maximally tolerated dose and the use of ezetimibe only when treatment goals are not achieved.


Related Articles

  • Ezetimibe/Simvastatin: A Review of its Use in the Management of Hypercholesterolemia. Murdoch, David; Scott, Lesley J. // American Journal of Cardiovascular Drugs;2004, Vol. 4 Issue 6, p405 

    Ezetimibe/simvastatin (Inegyâ„¢, Vytorinâ„¢) therapy combines two lipid-lowering compounds with complementary mechanisms of action, thereby blocking the two sources of plasma cholesterol and improving lipid profiles. Thus, intestinal absorption of dietary cholesterol and related...

  • Harsh spotlight falls on Vytorin. Wadman, Meredith // Nature Medicine;May2008, Vol. 14 Issue 5, p471 

    The article reports on the failure of Vytorin, a cholesterol drug combination from Merck and Schering-Plough, to provide a fighting plaque buildup in arteries in a randomized clinical trial. Principal investigator John Kastelein warned the company regarding the delay of the release of the...

  • All clear for now. Barry, Isobel // Nature Reviews Cancer;Oct2008, Vol. 8 Issue 10, p738 

    The article discusses the results of a clinical trial of Inegy, a combination of ezetimibe with the generic statin simvastatin configured to lower cholesterol. In July 2008, higher cancer incident was reported among the treated group. Researchers on Simvastin and Ezetimibe in Aortic Stenosis...

  • Statins—Is There Potential for Uncovering New Benefits (or Detriments)? Blazing, Michael // Cardiovascular Therapeutics;Apr2010, Vol. 28 Issue 2, p67 

    Despite over 20 years of clinical use and 15 years of clinical trial data, we still do not have a complete understanding of the mechanisms of action or full utility of statins as a class of drugs. The possibility of their use as a treatment for prevention of peri-operative morbidity and...

  • A Current Approach to Statin Intolerance. Tompkins, R; Schwartzbard, A; Gianos, E; Fisher, E; Weintraub, H // Clinical Pharmacology & Therapeutics;Jul2014, Vol. 96 Issue 1, p74 

    Statins are the first-line pharmacotherapy for cholesterol reduction. Use of these drugs in large randomized clinical trials has consistently shown significant reductions in major vascular events, including death, myocardial infarction, stroke, and coronary revascularization. The updated...

  • Cholesterol controversy. Richardson, Vanessa // Self;Feb97, Vol. 19 Issue 2, p56 

    Discusses the controversy over the United States government's National Cholesterol Education Program guidelines calling for regular cholesterol checks beginning at age 20. Risk of overprescription of cholesterol-lowering statin drugs; Long-term effects of cholesterol-lowering drugs.

  • Sucampo Presents Data for AMITIZA(r) in the Treatment of Moderate to Very Severe Irritable Bowel Syndrome with Constipation (IBS-C).  // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1 

    The article offers information on the results of phase three clinical studies conducted by Sucampo Pharmaceuticals Inc. to demonstrate the efficacy of the drug, Amitiza in treatment of irritable bowel syndrome with constipation. The results related with the study were presented at Digestive...

  • Gabapentin and nortriptyline combined was better than either drug alone for relief of neuropathic pain. Hughes, James // ACP Journal Club;3/16/2010, Vol. 152 Issue 3, p5 

    The article focuses on a medical research related to effectiveness of combined gabapentin and nortriptyline in comparison to alone drug for neuropathic pain. In a clinical trial around 56 patients with neuropathy is being observed and treated with combined drugs. It concluded that gabapentin and...

  • Withholding intravenous drugs did not improve survival to hospital discharge in out-of-hospital cardiac arrest. Stiell, Ian G. // ACP Journal Club;3/16/2010, Vol. 152 Issue 3, p7 

    The article offers information on a medical research related to intravenous drugs. It explores the effectiveness of withholding intravenous (IV) drugs in improvement of patient's health with out-of-hospital cardiac arrest. It concludes in a clinical trial that withholding intravenous drugs did...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics